Eniola's most defensible angle — if she proceeds at all — is to reframe IMPRINT or TOPOLOGIX (not the CCT model itself) as the primary commercial product: AI-native drug-liability screening or TDA-based drug–protein interaction SaaS platforms, with the CCT framework as proprietary scientific IP underlying them. This pivot to a software product with a credible B2B market (pharma, biotech, CRO) is closer to what EIC Accelerator has funded in the AI/health intersection (e.g., IKTOS, NannyML, Deeploy). Eniola would need to submit Step 1 from Nigeria while simultaneously incorporating ZYCO (or a new entity) in Austria by October 2026 (aligning with her planned Graz MSc move), then submit the full proposal from an EU-registered entity — a difficult but technically legal path given that Austria is an EU Member State.